Clinic Roundup

• Galectin Therapeutics Inc., of Newton, Mass., said the first patient was dosed in a Phase I/II trial testing GM-CT-01, its carbohydrate-based galectin inhibitor, in combination with a peptide vaccine furnished by the Ludwig Institute for Cancer Research in advanced metastatic melanoma. The primary endpoint is partial or complete response.